10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.

Autor: Antunes A; MabDesign, Lyon, France., Alvarez-Vallina L; Cancer Immunotherapy Unit (UNICA), Department of Immunology, Hospital Universitario 12 de Octubre, Madrid, Spain.; H120-CNIO Cancer Immunotherapy Clinical Research Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain., Bertoglio F; Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Department of Biotechnology, Braunschweig, Germany, Current address., Bouquin N; REGIMBEAU, Paris - 69006 Lyon, France., Cornen S; Innate Pharma, Marseille, France., Duffieux F; Large Molecules Research, Sanofi, Vitry-Sur-Seine, France., Ferré P; Compugen Ltd, Holon, Israel., Gillet R; REGIMBEAU, Paris - 69006 Lyon, France., Jorgensen C; IRMB, université de Montpellier, Inserm U1183, Montpellier, France.; Unité d'immunologie clinique et de thérapeutique des maladies ostéoarticulaires, département de rhumatologie, hôpital Lapeyronie, Montpellier, France., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA., Maillère B; Université de Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France., Negre H; Institut de Recherches Internationales Servier, Suresnes, France., Pelegrin M; IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France., Poirier N; OSE Immunotherapeutics, Nantes, France., Reusch D; Pharma Technical Development Analytics Biologics, Roche Diagnostics GmbH, Penzberg, Germany., Robert B; IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France., Serre G; Institut Toulousain des maladies infectieuses et inflammatoires - INFINITY- Inserm, CNRS, Université Toulouse III, Toulouse, France., Vicari A; Calypso Biotech SA, Plan-les-Ouates, Switzerland., Villalba M; IRMB, Univ Montpellier, INSERM, CNRS, Montpellier, France., Volpers C; Michalski Huettermann & Partner, Frankfurt/Main, Germany., Vuddamalay G; MabDesign, Lyon, France., Watier H; CEPR, INSERM U1100 Université de Tours, et CHU de Tours, Tours cedex, France., Wurch T; Evotec, Toulouse, France., Zabeau L; Orionis Biosciences BV, Ghent, Belgium., Zielonka S; Protein Engineering and Antibody Technologies, Merck Healthcare KGaA, Darmstadt, Germany., Zhang B; Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA., Beck A; Biologics CMC & Developability, Institut de Recherche Pierre Fabre, St Julien-en-Genevois Cedex, France., Martineau P; IRCM, INSERM, U1194 Univ Montpellier, ICM, 208, rue des Apothicaires, Montpellier, France.
Jazyk: angličtina
Zdroj: MAbs [MAbs] 2023 Jan-Dec; Vol. 15 (1), pp. 2211692.
DOI: 10.1080/19420862.2023.2211692
Abstrakt: The annual "Antibody Industrial Symposium", co-organized by LabEx MAbImprove and MabDesign, held its 10th anniversary edition in Montpellier, France, on June 28-29, 2022. The meeting focused on new results and concepts in antibody engineering (naked, mono- or multi-specific, conjugated to drugs or radioelements) and also on new cell-based therapies, such as chimeric antigenic receptor (CAR)-T cells. The symposium, which brought together scientists from academia and industry, also addressed issues concerning the production of these molecules and cells, and the necessary steps to ensure a strong intellectual property protection of these new molecules and approaches. These two days of exchanges allowed a rich discussion among the various actors in the field of therapeutic antibodies.
Databáze: MEDLINE